No Data
No Data
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy
Autolus Therapeutics Presents Clinical Data on Obe-cel Treatment
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
Autolus Therapeutics (NASDAQ:AUTL) Shareholder Returns Have Been Decent, Earning 76% in 1 Year
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading
No Data
No Data